Skip to main content

Qiagen, TIGR, and Montefiore Pen Genotyping Agreement

NEW YORK, March 14 – Genotyping technology company Qiagen Genomics said Wednesday it had reached a research and licensing agreement with The Institute for Genomic Research and the Montefiore Medical Center to conduct an association study of SNPs in Mycobaterium tuberculosis , the bacterium that causes tuberculosis. 

Under the terms of the deal, Qiagen Genomics, a subsidiary of Qiagen NV, has the exclusive license from TIGR to make and sell kits or other products based on certain M. tuberculosis  SNP patents and some of TIGR’s intellectual property. Qiagen also has the right to use and to license to others TIGR's M. tuberculosis  SNP patents.

The deal follows on the heals of two studies performed by Qiagen and TIGR, using Qiagen’s Masscode technology to genotype M. tuberculosis  SNPs. In the initial pilot study, the Masscode system was used to analyze 12 of approximately 1,100 previously identified M. tuberculosis  SNPs. The pilot study provided an average call rate, defined as the total number of genotype measurements that were obtained divided by the total number of measurements possible, of 99.5 percent. 

In the next study, Qiagen, TIGR, and MMC analyzed the 12 SNPs plus an additional 100  M. tuberculosis  SNPs against 2 reference-strain DNA samples and 170 clinical isolates of M. tuberculosis . Results of the second study demonstrated the application of the Masscode system in genotyping loci of the highly infectious microbe.

"We were very pleased by the accurate, rapid and robust results generated from use of the Masscode system in these studies," said Claire Fraser, president of TIGR.

Fraser said TIGR would continue to use Masscode to find SNPs in other pathogens.

The Masscode system combines the company’s chemistry, known as Masscode tags, with the single quadrupole mass spectrometer, which quantifies the results.

Terms of the deal were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.